Table 3.
Overall survival and treatment free survival results in 165 chronic lymphocytic leukemia (CLL) patients
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | ||
| OS | |||||
| Binet stage | B + C vs A | 4.65 (2.38–7.65) | 0.001 | 2.23 (1.14–4.34) | 0.029 |
| β2‐MG | >4 mg/L vs <4 mg/L | 2.81 (1.06–4.98) | 0.027 | 1.98 (0.76–1.28) | 0.281 |
| p53 status | p53 attenuated vs p53 wildtype | 6.38 (2.17–26.33) | <0.001 | 3.88 (1.78–6.54) | 0.018 |
| IGHV status | Unmutated vs Mutated | 7.32 (2.66–18.44) | 0.002 | 1.55 (0.86–2.12) | 0.198 |
| CD38 | >30% vs ≤ 30% | 1.28 (0.84–3.77) | 0.146 | N/A | N/A |
| ZAP70 | >20% vs ≤ 20% | 1.32 (0.76–2.32) | 0.486 | N/A | N/A |
| Dicer expression | Low vs high | 6.22 (1.75–21.94) | 0.005 | 1.30 (0.73–2.24) | 0.420 |
| TFS | |||||
| Binet stage | B + C vs A | 3.89 (2.67–8.14) | 0.001 | 3.77 (1.07–4.13) | 0.013 |
| β2‐MG | >4 vs ≤4 mg/L | 2.25 (0.96–5.30) | 0.038 | 1.23 (0.56–2.07) | 0.38 |
| p53 status | p53 attenuated vs p53 wildtype | 1.89 (1.11–4.23) | 0.137 | N/A | N/A |
| IGHV status | Unmutated vs mutated | 2.03 (0.78–6.14) | 0.008 | 1.78 (0.88–2.65) | 0.067 |
| CD38 | >30% vs ≤ 30% | 1.81 (0.80–3.38) | 0.012 | 1.92 (0.74–3.14) | 0.030 |
| ZAP70 | >20% vs ≤ 20% | 1.13 | 0.334 | N/A | N/A |
| Dicer expression | Low vs high | 2.32 (1.44–3.76) | 0.001 | 1.65 (0.96–2.43) | 0.073 |
CD38 and ZAP70 have not been included in multivariate analysis of overall survival (OS). p53 status and ZAP70 have not been included in multivariate analyses of treatment free survival (TFS). These are indicated as N/A (not available). P‐values less than 0.05 were considered significant and are in bold. CI, confidence interval; HR, hazard ratio; IGHV, immunoglobulin heavy chain variable gene.